Skip to main content

Table 1 Characteristics of 2638 patients hospitalized with incident Staphylococcus aureus bacteremia in Northern Denmark, 2000-2011

From: Chronic heart failure and mortality in patients with community-acquired Staphylococcus aureus bacteremia: a population-based cohort study

 

Patients with chronic heart failure

Patients without chronic heart failure

Numbers (%)

390 (14.8)

2248 (85.2)

Age, median (IQR)

76.6 (66.9–82.2)

67.4 (54.4–78.3)

 15–39 years

12 (3.1)

221 (9.8)

 40–59 years

48 (12.3)

557 (24.8)

 60–79 years

194 (49.7)

988 (44.0)

  ≥ 80 years

136 (34.9)

482 (21.4)

Sex

  

 Men

253 (64.9)

1363 (60.6)

 Women

137 (35.1)

885 (39.4)

S.aureus bacteremia

  

 Community-acquired

203 (52.1)

1320 (58.7)

 Healthcare-associated

187 (48.0)

928 (41.3)

 MRSA

3 (0.8)

10 (0.4)

Marital status

  

 Married

203 (52.1)

1067 (47.5)

 Divorced or widowed

152 (39.0)

734 (32.7)

 Never married

35 (9.0)

447 (19.9)

Selected comorbid conditions

  

 Diabetes mellitus

121 (31.0)

287 (12.8)

 Peripheral vascular disease

99 (25.4)

229 (10.2)

 Cerebrovascular disease

76 (19.5)

239 (10.6)

 Chronic pulmonary disease

120 (30.8)

243 (10.8)

 Moderate to severe renal disease

130 (33.3)

306 (13.6)

 Hypertension

193 (49.5)

458 (20.4)

 Conditions related to alcohol abuse

26 (6.7)

209 (9.3)

 Conditions related to drug abuse

4 (1.0)

69 (3.1)

 Dialysis within 30 days of admission

61 (15.6)

203 (9.0)

Modified Charlson Comorbidity Index

  

 Low (0)

42 (10.8)

720 (32.0)

 Intermediate (1–2)

129 (33.1)

826 (36.7)

 High (>2)

219 (56.2)

702 (31.2)

Preadmission medication use

  

 Immunosuppressive therapya

3 (0.8)

25 (1.1)

 Systemic antibiotic therapya

82 (21.0)

454 (20.2)

 ACE inhibitorsb

298 (76.4)

788 (35.1)

 Beta blockersb

271 (69.5)

764 (34.0)

 Acetylsalicylic acidb

301 (71.2)

820 (36.5)

 Statinsb

174 (44.6)

451 (20.1)

Clinical biochemistry

  

White blood count (109/L)c

  

  < 3.5

11 (2.8)

100 (4.5)

 3.5–10

52 (13.3)

440 (19.6)

  > 10

262 (67.2)

1292 (57.5)

 Unknown

65 (16.7)

416 (18.5)

  1. IQR interquartile range, MRSA methicillin resistant Staphylococcus aureus, ACE inhibitors angiotensin-converting-enzyme inhibitors
  2. aAny use within 30 days of the current admission. bAny previous use prior to the current admission
  3. cMeasured on the date the first positive blood culture was drawn